Navigation Links
Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
Date:9/10/2007

ad range of applications -- including Windows, Web, and terminal-based -- can be easily generated. In addition, expreSSO includes a catalog of pre-built SSO application connectors, which Sentillion continues to expand, that provide "off the shelf" application integration to even further accelerate the speed of deployment and clinical adoption.

Additional key features and benefits of expreSSO include:

-- Support for graceful single sign off in addition to single sign on,

-- Fast User Switching, enabling users to log on and off of shared

workstations in a matter of seconds,

-- Built-in support for strong authentication including fingerprint

biometrics, active proximity, or passive proximity and combinations of

these technologies,

-- Enterprise Grace Period to enable organizations to automatically adjust

the type of authentication required during the course of each

caregiver's work day,

-- Secure self-service password reset, even on a locked workstation, to

eliminate help desk calls,

-- Intelligent agent technology with extensive catalog of application

connectors for rapid SSO integration with Windows, web, and terminal

applications,

-- Unique animated wizard for rapid point-and-click generation of new

application connectors when needed,

-- Quick-start wizard for expedited system set-up,

-- Plug-and-go with automatic user identity import and ongoing

synchronization with enterprise directories along with automated

application password learning to enable rapid deployment,

-- Easy to use centralized system administration with automatic event

notification,

-- A proven appliance-based five-nines (99.999% uptime) fault tolerant

architecture capable of supporting and maintaining more than 100,000

users,

-- Scalable from departmental to enterprise-wide to national deployments
'/>"/>

SOURCE Sentillion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. TI Cycles Introduces Foldman
3. Canada Introduces Mandatory Nutrition Labeling
4. Amgen introduces Autoinjector For Treating Anemia
5. Cuba Introduces New Device for Detecting Vascular Diseases
6. China Introduces Solar-powered Baths
7. Allergan Introduces ‘Dermal Filler’ for Smile Lins
8. UAE Introduces Cervical Cancer Vaccine
9. Cynosure Introduces Higher Power Smartlipo(TM) LaserBodySculpting Workstation
10. Iceland Introduces Smoking Ban in Bars and Restaurants
11. Indian Introduces Paan-flavoured Condoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...ica who had treated injured protestors while takin...red to // leave Nepal by the King Gyanendra's gove...reportedly detained Wednesday after he appeared on...ipur television channel that truncheon-wielding po...
...gograd, in Russia, has reported the deadly H5N1 st...rom the state veterinary authorities.// This is t...ns in Southern Russia have reported Bird-Flu infec...t died in Volgograd, have tested positive for the ...
... India, which is in its infancy demands a lot of f... Indian Council of Medical Research (ICMR).// ...allenges in stem cell research in India', Ganguly ...nding and a regulatory framework for ethical pract...
...o reverse the process of cell division. This proce...inding could be an important milestone in the figh...llably. Researchers from the Oklahoma Medical ...r, there has to be a perfect co-ordination between...
... suicide rate in England is at its lowest ever wit...population from 2002 to 2004. It is also noted tha...steady fall in the number of young men committing ...ointly issued by the Department of Health and the ...
...perts about the hearing loss caused by the MP3 pla...hout paying// any heed to those warnings. But sens...s have now started limiting the volume on the devi...s. The ASHA said having the volume up too loud and...
Other Medicine News:Health News:Sensing The Health Hazard MP3 Makers Tone Down The Volume 2
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 1AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 2Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 1Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 2Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 3Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 4Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 5Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 6Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 7Child Food Allergies on the Rise in U S 61410 1Child Food Allergies on the Rise in U S 61410 2Child Food Allergies on the Rise in U S 61410 3
...nificant Reduction in Relapse Rate , , - Secondar... of Patients Relapse-Free and Disability Progressi...e Tablets Planned for mid-2009 , , SEATTLE and GE...KGaA, announced today detailed results of the two-... III trial using Cladribine Tablets (Merck Serono,...
...y and safety for extended release and immediate re...ril 29 /PRNewswire/ -- New findings from two dou...ty and tolerability of pramipexole dihydrochloride...ation, for the treatment of Parkinson,s disease (P...emy of Neurology (AAN) 61st Annual Meeting in Seat...
Other Medicine Technology:Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 2Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 3Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 4Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 5Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 6Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 7New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 2New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 3New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 4New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 5
Full Body Girdle V-1655
Body Suit w/Bra above knee, Front Closure
Compression Vest V-640
Male Compression Vest Binder
Medicine Products: